|
|
Article: King Pharmaceuticals Announces Completion of Patient Enrollment in Altace(R) Pediatric Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- November 3, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
King Pharmaceuticals, Inc. announced today the completion of enrollment in the ongoing Phase IV clinical trial to determine the safety and effectiveness of Altace(R) (ramipril), an ACE (angiotensin converting enzyme) inhibitor, in the treatment of hypertension (high blood pressure) in children. This important trial known as TOPHAT (Treatment of Pediatric Hypertension with Altace Trial) is scheduled to conclude by the end of 2004.
Jefferson J. Gregory, Chairman and Chief Executive Officer of King, stated, "King has assembled a strong portfolio of drugs that improve people's lives. As a fully integrated pharmaceutical company, with a substantial R&D capability, ...